Corvus Pharmaceuticals Inc
Research Corvus Pharmaceuticals Inc (CRVS) on Bullrun: market cap USD 1.22B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCRVS
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 1.22B
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 17.96M
- Free cash flow-USD 15.98M
Valuation Snapshot
latest market cap is USD 1.22B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 15.30M | -USD 32.97M | n/a | -0.53 | USD 4.58M | USD 937.00K | USD 61.21M |
| FY2024 | USD 0 | -USD 62.30M | -USD 25.42M | n/a | -1.02 | USD 8.74M | USD 1.12M | USD 32.57M |
| FY2023 | n/a | -USD 27.00M | -USD 23.97M | n/a | -0.56 | USD 12.62M | USD 1.37M | USD 38.68M |
| FY2022 | n/a | -USD 41.31M | -USD 27.29M | n/a | -0.89 | USD 13.16M | USD 3.13M | USD 56.12M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 1.22B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 575.16M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 363.26M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 86.31M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 39.57M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 112.19M | n/a | n/a | n/a |
About Corvus Pharmaceuticals Inc
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States.
Related stock research
Other Healthcare stocks
Adicet Bio Inc (1IJ)
Cartesian Therapeutics, Inc. (1S70)
QUOIN PHARMACEUT.ADR5000 (2EB0)
Aardvark Therapeutics Inc (AARD)
Abeona Therapeutics Inc (ABEO)
Acumen Pharmaceuticals Inc (ABOS)
Absci Corp (ABSI)
Arbutus Biopharma Corp (ABUS)
ABVC BioPharma Inc (ABVC)
Acadia Pharmaceuticals Inc (ACAD)
Adicet Bio Inc (ACET)
Achieve Life Sciences Inc (ACHV)
Frequently asked questions
What is Corvus Pharmaceuticals Inc's market cap?
Corvus Pharmaceuticals Inc's market capitalization is USD 1.22B.
What does Corvus Pharmaceuticals Inc do?
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States.